Skip to main content

Table 5 Changes in liver function and HbA1c after pemafibrate treatment

From: Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

Characteristic

Weeks after pemafibrate treatment

Pemafibrate treatment

Week −8

Week −4

Week 0

Week 4

Week 8

Week 12

Week 16

Week 20

Week 24

P*

Baselinea

Post-doseb

P**

AST, median (IQR),

IU/L

            

 Total

21 (18–29)

22 (18–30)

23 (19–33)

21 (18–34)

23 (18–31)

24 (21–44)

23 (19–29)

22 (19–33)

21 (19–29)

0.9212

23 (18–31)

23 (19–31)

0.9139

 Increased LDL-C group (group I)

23 (19–34)

26 (21–33)

23 (20–36)

19 (18–32)

20 (17–33)

26 (21–48)

23 (18–40)

23 (20–43)

20 (19–22)

0.6619

23 (19–34)

21 (18–34)

0.3833

 No LDL-C increase group (group NI)

20 (17–27)

20 (17–29)

20 (18–29)

21 (19–35)

24 (19–28)

23 (21–40)

24 (20–28)

21 (17–49)

23 (16–34)

0.9440

20 (18–28)

25 (20–29)

0.6184

 P***

0.2611

0.1970

0.1894

0.4655

0.3690

0.6480

0.9545

0.5388

0.8421

 

0.2273

0.4646

 

ALT, median (IQR),

IU/L

            

 Total

22 (18–36)

26 (18–37)

23 (18–40)

19 (16–29)

20 (17–27)

19 (17–58)

21 (16–31)

18 (15–23)

17 (15–24)

0.1297

24 (17–37)

19 (16–30)

0.0010

 Increased LDL-C group (group I)

28 (19–40)

30 (19–39)

31 (19–41)

19 (17–28)

20 (15–38)

19 (16–62)

23 (17–38)

19 (15–33)

18 (14–25)

0.1802

31 (21–40)

19 (16–34)

0.0040

 No LDL-C increase group (group NI)

22 (17–29)

23 (16–36)

20 (17–29)

19 (15–38)

20 (17–25)

17 (17–53)

21 (16–30)

18 (14–53)

17 (15–24)

0.9352

22 (17–29)

21 (17–26)

0.0909

 P***

0.1606

0.1605

0.0582

1.0000

0.9269

0.9091

0.5141

1.0000

0.8427

 

0.0520

0.9918

 

γGTP, median (IQR),

IU/L

            

 Total

34 (26–94)

46 (28–83)

39 (24–92)

34 (21–48)

30 (18–47)

43 (31–74)

28 (15–57)

34 (20–57)

33 (20–65)

0.0656

37 (26–86)

31 (19–54)

<0.0001

 Increased LDL-C group (group I)

43 (31–98)

67 (31–110)

53 (28–102)

39 (29–60)

32 (22–53)

53 (32–80)

37 (14–71)

40 (29–67)

38 (25–71)

0.2944

48 (28–101)

34 (26–75)

< 0.0001

 No LDL-C increase group (group NI)

31 (20–77)

36 (24–63)

32 (18–54)

20 (12–49)

23 (17–34)

31 (14–44)

25 (16–47)

18 (13–46)

31 (15–49)

0.4730

30 (19–62)

26 (17–43)

<0.0001

 P***

0.0975

0.0643

0.0382

0.1118

0.1074

0.0471

0.2486

0.0570

0.1392

 

0.0600

0.0992

 

HbA1c, mean (SD),

%

            

 Total

7.5 (1.5)

7.7 (1.5)

7.4 (1.6)

7.6 (1.2)

7.4 (1.6)

7.2 (1.4)

7.2 (1.3)

7.9 (1.4)

7.1 (1.9)

0.7897

7.4 (1.4)

7.3 (1.5)

0.0502

 Increased LDL-C group (group I)

7.6 (1.7)

7.5 (1.3)

7.2 (1.1)

7.4 (1.3)

7.3 (1.3)

7.0 (1.6)

7.3 (1.4)

7.7 (1.8)

6.7 (1.4)

0.8251

7.2 (1.3)

7.1 (1.3)

0.1510

 No LDL-C increase group (group NI)

7.5 (2.0)

8.0 (1.6)

7.5 (2.0)

7.8 (1.1)

7.5 (1.9)

7.4 (1.1)

7.2 (1.3)

8.1 (0.8)

7.4 (2.3)

0.9534

7.5 (1.5)

7.4 (1.6)

0.1561

 P***

0.7866

0.3344

0.5476

0.5551

0.6126

0.6060

0.7508

0.6851

0.3621

 

0.5568

0.4819

 
  1. P<0.05 was considered statistically significant. *, Statistical analysis was done using the Kruskal-Wallis test or ANOVA. aMean value of 3 measurements before pemafibrate; bMean value of 6 measurements after pemafibrate. **, Statistical analysis was done using Wilcoxon signed-rank test or paired t-test. ***, Statistical analysis between 2 groups I and NI was done using the Mann-Whitney U test or t-test. LDL-C Low density lipoprotein cholesterol, HbA1c Glycated hemoglobin
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X